NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

GILD

Gilead Sciences, Inc

Jul 03 • 04:00PM ET

111.75

Dollar change +0.24
Percentage change 0.22	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: ABBV BMY MRK PFE AMGN JNJ LLY VRTX REGN BIIB

| Held by: VTI VOO QQQ SPY IVV VTV XLV VYM QQQM VHT

Scroll to Statements

Index	NDX, S&P 500	P/E	23.50	EPS (ttm)	4.76	Insider Own	0.16%	Shs Outstand	1.25B	Perf Week	3.84%
Market Cap	139.01B	Forward P/E	13.04	EPS next Y	8.57	Insider Trans	-15.45%	Shs Float	1.24B	Perf Month	2.21%
Enterprise Value	154.75B	PEG	0.90	EPS next Q	1.94	Inst Own	86.79%	Short Float	1.85%	Perf Quarter	-0.13%
Income	5.96B	P/S	4.85	EPS this Y	72.50%	Inst Trans	0.38%	Short Ratio	2.48	Perf Half Y	21.45%
Sales	28.69B	P/B	7.26	EPS next Y	7.56%	ROA	10.58%	Short Interest	22.99M	Perf YTD	20.98%
Book/sh	15.39	P/C	15.23	EPS next 5Y	26.05%	ROE	32.51%	52W High	119.96 -6.84%	Perf Year	62.81%
Cash/sh	7.34	P/FCF	14.12	EPS past 3/5Y	-57.36% -38.13%	ROIC	14.44%	52W Low	66.01 69.29%	Perf 3Y	79.63%
Dividend Est.	3.25 (2.91%)	EV/EBITDA	11.31	Sales past 3/5Y	1.62% 5.17%	Gross Margin	78.25%	Volatility	2.15% 2.42%	Perf 5Y	49.86%
Dividend TTM	3.12 (2.79%)	EV/Sales	5.39	EPS Y/Y TTM	1144.01%	Oper. Margin	38.01%	ATR (14)	2.70	Perf 10Y	-7.05%
Dividend Ex-Date	Jun 13, 2025	Quick Ratio	1.23	Sales Y/Y TTM	4.63%	Profit Margin	20.79%	RSI (14)	57.95	Recom	1.87
Dividend Gr. 3/5Y	2.74% 4.10%	Current Ratio	1.37	EPS Q/Q	131.24%	SMA20	1.77%	Beta	0.35	Target Price	117.64
Payout	805.23%	Debt/Eq	1.30	Sales Q/Q	-0.60%	SMA50	4.63%	Rel Volume	0.44	Prev Close	111.51
Employees	17600	LT Debt/Eq	1.16	Earnings	Apr 24 AMC	SMA200	12.85%	Avg Volume	9.25M	Price	111.75
IPO	Jan 22, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.66% -2.11%	Trades		Volume	4,039,811	Change	0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$125
Mar-04-25	Reiterated	Oppenheimer	Outperform	$115 → $132
Feb-18-25	Upgrade	Deutsche Bank	Hold → Buy	$120
Feb-13-25	Upgrade	DZ Bank	Hold → Buy	$108
Jan-10-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$87 → $113
Dec-10-24	Resumed	BofA Securities	Buy	$109
Nov-15-24	Initiated	Wolfe Research	Outperform	$110
Nov-14-24	Initiated	Citigroup	Buy	$125
Nov-08-24	Downgrade	Maxim Group	Buy → Hold
Oct-21-24	Upgrade	Leerink Partners	Market Perform → Outperform	$74 → $96
Oct-17-24	Initiated	Bernstein	Outperform	$105
Oct-07-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$78 → $100
Jul-08-24	Upgrade	Raymond James	Mkt Perform → Outperform	$93
May-01-24	Reiterated	Maxim Group	Buy	$90 → $85
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold	$69
Feb-22-24	Downgrade	Truist	Buy → Hold	$91 → $82
Nov-09-23	Initiated	Deutsche Bank	Hold	$75
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy	$88 → $95
Sep-06-23	Initiated	HSBC Securities	Reduce	$71
Jul-24-23	Reiterated	Barclays	Equal Weight	$81 → $80

Show Previous Ratings

Jul-03-25 02:47AM	Gilead Sciences (GILD) Announces that US FDA Approves Yeztugoas pre-exposure prophylaxis (PrEP) (Insider Monkey)
Jul-01-25 07:00PM	Gilead Sciences: A Mixed Bag of Opportunities and Risks (Motley Fool)
05:32AM	Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 \| Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth (GlobeNewswire)
Jun-30-25 07:55AM	Gilead extends gains after Supreme Court upheld an Obamacare provision (Investing.com)
06:20AM	Should You Invest in the VanEck Biotech ETF (BBH)? (Zacks)
04:16AM	Loading…
Jun-28-25 04:16AM	Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer (Insider Monkey)
Jun-27-25 05:50PM	Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
04:25PM	Gilead, Exact Jump After The Supreme Court Upholds A 'Cornerstone' Of Health Care (Investor's Business Daily)
11:11AM	Gilead Rises After Supreme Court Says Insurers Must Cover HIV Prevention Drugs (Investor's Business Daily)
10:22AM	Why This Looming Supreme Court Decision Could Rattle Gilead Sciences (Investor's Business Daily)
10:19AM	Kymeras partnerships with Sanofi and Gilead drive value (Investing.com)
09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
09:00AM	Debut Named to TIME's List of the TIME100 Most Influential Companies 2025 (PR Newswire)
Jun-26-25 12:45PM	Northwell Health named to TIME100 Most Influential Companies 2025 list (Business Wire)
10:45AM	Kymera weakness a buying opportunity, says Stifel (TipRanks)
10:16AM	Loading…
10:16AM	Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. (Investor's Business Daily)
09:06AM	Morning Movers: General Mills dips following fourth quarter report (TipRanks)
08:40AM	KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update (Zacks)
Jun-25-25 06:00PM	Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know (Zacks)
03:09PM	Alger Russell Innovation Index Updates for Second Quarter 2025 (PR Newswire)
01:15PM	FDA approves Gileads twice-yearly injectable Yeztugo for PrEP (Clinical Trials Arena)
01:04PM	Gilead eyes Kymeras adhesive cancer drug in $750m deal (Pharmaceutical Technology)
08:07AM	Kymera adds Gilead as research partner, while advancing new candidate with Sanofi (BioPharma Dive)
08:00AM	Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B (GlobeNewswire)
07:00AM	Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders (Business Wire)
Jun-24-25 12:15PM	EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch (Zacks)
Jun-23-25 01:52PM	Squawk Pod: The U.S.-Iran escalation explained - 06/23/25 Audio Only (CNBC TV)
11:00AM	Gilead Sciences CEO Daniel O'Day on HIV prevention injection approval (CNBC TV)
09:51AM	Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV (CNBC TV)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
06:20AM	Loading…
06:20AM	Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar? (Zacks)
Jun-22-25 11:22PM	5 Insightful Analyst Questions From Gilead Sciences's Q1 Earnings Call (StockStory)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
08:05AM	BMO says lenacapavir approval for prevention a major win for Gilead (TipRanks)
Jun-19-25 01:30PM	FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention (Zacks)
09:50AM	Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term (Zacks)
05:24AM	Gilead Sciences Yeztugo receives approval from US FDA for HIV (Pharmaceutical Technology)
Jun-18-25 10:49PM	Celltrion opens new UK headquarters in Uxbridge, UK (Business Wire)
05:12PM	Gilead's twice-yearly HIV prevention injection gets FDA approval (Yahoo Finance Video)
04:41PM	Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It? (Investor's Business Daily)
04:04PM	FDA Approves Gilead's HIV Shot. It Works 99.9% of the Time. (Barrons.com)
03:43PM	FDA Approves Powerful Twice-Yearly Treatment to Prevent HIV (The Wall Street Journal)
02:57PM	Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug (Investor's Business Daily)
02:52PM	The world's only twice-a-year shot to prevent HIV could stop transmission if people can get it (Associated Press Finance)
02:52PM	FDA approves the world's only twice-a-year shot to prevent HIV (Associated Press Finance)
02:49PM	Yeztugo (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection (Business Wire)
11:02AM	FDA approves twice-yearly shot of Gilead drug for HIV prevention (BioPharma Dive)
Jun-15-25 05:47AM	Goldman Sachs Reiterates a Hold Rating on Gilead Sciences (GILD) (Insider Monkey)
05:38AM	RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey (Insider Monkey)
Jun-12-25 09:00AM	Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know (Zacks)
Jun-11-25 10:20AM	Citi sees Gilead clinical holds as only minor setback (TipRanks)
10:20AM	Gilead weekly oral hold should not affect lenacapavir PDUFA, says RBC Capital (TipRanks)
10:15AM	FDA placed clinical hold on Gilead HIV treatment trials of GS-1720 (TipRanks)
09:47AM	FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down (Zacks)
09:30AM	Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views? (Zacks)
Jun-10-25 05:22PM	Why Gilead Scinces Stock Tumbled on Tuesday (Motley Fool)
09:59AM	Gilead Sciences shares hit after HIV studies placed on hold by FDA (Investing.com)
Jun-09-25 06:20AM	Should You Invest in the iShares Biotechnology ETF (IBB)? (Zacks)
Jun-06-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
12:01AM	2 Reasons to Like GILD (and 1 Not So Much) (StockStory)
Jun-05-25 05:30AM	A New Shot Prevents HIV-and Breathes New Life Into a Stagnant Biotech (The Wall Street Journal)
Jun-03-25 11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
12:31AM	1 Healthcare Stock Worth Your Attention and 2 to Turn Down (StockStory)
Jun-02-25 09:38AM	Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study (Zacks)
Jun-01-25 08:00AM	Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025 (Business Wire)
May-31-25 08:08AM	Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial (Reuters)
08:00AM	Trodelvy Plus Keytruda Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (Business Wire)
May-30-25 11:09AM	Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold? (Zacks)
09:11AM	Stock Market News for May 30, 2025 (Zacks)
May-29-25 11:30AM	Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report? (Zacks)
09:00AM	Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock (Zacks)
May-27-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)
May-26-25 09:16AM	GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer (Zacks)
04:47AM	Gileads Phase III trial for breast cancer therapy meets primary goal (Clinical Trials Arena)
May-24-25 08:40AM	Gilead announces ASCENT-03 study meets primary endpoint (TipRanks)
May-23-25 10:42AM	Gilead (GILD) to Acquire HOOK for $10 million (Insider Monkey)
08:30AM	ASCENT-03: Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors (Business Wire)
May-21-25 09:40AM	Here's Why Gilead Sciences (GILD) is a Strong Value Stock (Zacks)
May-20-25 12:56PM	Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now? (Zacks)
06:20AM	Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? (Zacks)
04:52AM	Stock Market News for May 20, 2025 (Zacks)
May-18-25 03:26PM	Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA (Insider Monkey)
May-15-25 04:15PM	Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA (Business Wire)
09:00AM	Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? (Zacks)
May-13-25 05:02PM	Why Gilead Sciences (GILD) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom (Insider Monkey)
May-12-25 10:44AM	Trump expected to sign order to slash US drug prices (Yahoo Finance Video) +7.13%
10:24AM	The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple (Zacks)
09:09AM	US-China trade truce, April CPI, drug prices: 3 Things (Yahoo Finance Video)
May-11-25 04:51PM	Is Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons' Renaissance Technologies? (Insider Monkey)
May-10-25 08:45AM	2 High-Yield Dividend Stocks to Buy in May and Hold Forever (Motley Fool)
May-09-25 05:00PM	Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton (Zacks) +7.13%
06:20AM	Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now? (Zacks)
12:38AM	3 Value Stocks with Mounting Challenges (StockStory)
May-08-25 10:27AM	Gilead reports final outcomes from trial of bulevirtide for chronic HDV (Clinical Trials Arena)
12:04AM	Hartford Dividend And Growth Fund Q1 2025 Commentary (Seeking Alpha)
May-07-25 10:19PM	How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock (Benzinga)
05:46PM	Gilead to Invest $11 Billion to Bolster Domestic Operations (The Wall Street Journal)
03:37PM	Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing (Investing.com)
03:14PM	Gilead to invest about $32B in U.S. manufacturing through 2030 (Seeking Alpha)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Day Daniel Patrick	Chairman & CEO	Jun 30 '25	Sale	110.45	10,000	1,104,484	615,725	Jul 01 06:02 PM
DANIEL O'DAY	Officer	Jun 30 '25	Proposed Sale	110.45	10,000	1,104,483		Jun 30 04:05 PM
Dickinson Andrew D	Chief Financial Officer	Jun 16 '25	Sale	110.17	2,500	275,425	165,110	Jun 17 06:08 PM
Mercier Johanna	Chief Commercial Officer	Jun 16 '25	Sale	110.17	3,000	330,510	120,168	Jun 17 06:04 PM
JOHANNA MERCIER	Officer	Jun 16 '25	Proposed Sale	110.17	3,000	330,510		Jun 16 04:05 PM
ANDREW DICKINSON	Officer	Jun 16 '25	Proposed Sale	110.17	2,500	275,425		Jun 16 04:01 PM
O'Day Daniel Patrick	Chairman & CEO	May 30 '25	Sale	110.42	10,000	1,104,193	620,268	Jun 02 08:55 PM
DANIEL O'DAY	Officer	May 30 '25	Proposed Sale	110.42	10,000	1,104,192		May 30 04:16 PM
Mercier Johanna	Chief Commercial Officer	May 22 '25	Option Exercise	66.64	25,000	1,666,000	136,652	May 23 03:16 PM
Mercier Johanna	Chief Commercial Officer	May 22 '25	Sale	107.52	28,000	3,010,564	121,152	May 23 03:16 PM
JOHANNA MERCIER	Officer	May 22 '25	Proposed Sale	107.52	28,000	3,010,562		May 22 04:01 PM
Dickinson Andrew D	Chief Financial Officer	May 15 '25	Sale	99.82	2,500	249,550	165,674	May 16 04:34 PM
ANDREW DICKINSON	Officer	May 15 '25	Proposed Sale	99.82	2,500	249,550		May 15 04:03 PM
Dickinson Andrew D	Chief Financial Officer	Apr 15 '25	Sale	106.40	2,500	266,000	168,174	Apr 16 03:22 PM
ANDREW DICKINSON	Officer	Apr 15 '25	Proposed Sale	106.40	2,500	266,000		Apr 15 04:04 PM
Dickinson Andrew D	Chief Financial Officer	Mar 17 '25	Sale	110.53	2,500	276,325	170,674	Mar 18 04:37 PM
ANDREW DICKINSON	Officer	Mar 17 '25	Proposed Sale	110.53	2,500	276,325		Mar 17 04:16 PM
Dickinson Andrew D	Chief Financial Officer	Mar 10 '25	Option Exercise	63.91	17,929	1,145,842	186,990	Mar 12 06:41 PM
Dickinson Andrew D	Chief Financial Officer	Mar 10 '25	Sale	118.17	17,929	2,118,696	169,061	Mar 12 06:41 PM
ANDREW DICKINSON	Officer	Mar 10 '25	Proposed Sale	118.17	17,929	2,118,695		Mar 10 04:02 PM
MERDAD V PARSEY	Officer	Mar 03 '25	Proposed Sale	115.70	21,910	2,534,913		Mar 03 04:26 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 18 '25	Buy	11.00	1,363,636	14,999,996	31,424,760	Feb 20 07:42 PM
Dickinson Andrew D	Chief Financial Officer	Feb 18 '25	Sale	104.09	2,500	260,225	169,061	Feb 19 04:43 PM
ANDREW DICKINSON	Officer	Feb 18 '25	Proposed Sale	104.09	2,500	260,225		Feb 18 04:14 PM
Dickinson Andrew D	Chief Financial Officer	Feb 12 '25	Option Exercise	67.27	137,676	9,260,873	308,899	Feb 13 09:13 PM
Dickinson Andrew D	Chief Financial Officer	Feb 12 '25	Sale	102.22	137,676	14,073,241	171,223	Feb 13 09:13 PM
ANDREW DICKINSON	Officer	Feb 12 '25	Proposed Sale	102.22	137,676	14,073,241		Feb 12 04:03 PM
Dickinson Andrew D	Chief Financial Officer	Jan 31 '25	Option Exercise	67.52	142,180	9,600,576	273,053	Feb 03 06:09 PM
Dickinson Andrew D	Chief Financial Officer	Jan 31 '25	Sale	97.22	142,180	13,822,740	129,873	Feb 03 06:09 PM
ANDREW DICKINSON	Officer	Jan 31 '25	Proposed Sale	97.22	142,180	13,822,740		Jan 31 04:15 PM
MERDAD V PARSEY	Officer	Jan 31 '25	Proposed Sale	98.00	184,683	18,098,989		Jan 31 04:01 PM
Dickinson Andrew D	Chief Financial Officer	Jan 15 '25	Sale	91.35	2,500	228,375	129,873	Jan 16 03:31 PM
ANDREW DICKINSON	Officer	Jan 15 '25	Proposed Sale	91.35	2,500	228,375		Jan 15 04:18 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 19 '24	Buy	21.37	940,499	20,098,464	2,209,471	Dec 23 08:26 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 18 '24	Buy	1.04	1,759,978	1,830,377	9,105,451	Dec 19 04:19 PM
Dickinson Andrew D	Chief Financial Officer	Dec 16 '24	Sale	91.96	8,500	781,660	132,373	Dec 17 05:27 PM
ANDREW DICKINSON	Officer	Dec 16 '24	Proposed Sale	91.96	8,500	781,660		Dec 16 04:08 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Option Exercise	70.50	248,645	17,528,577	387,564	Dec 03 02:43 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Sale	92.76	248,645	23,065,271	138,919	Dec 03 02:43 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Option Exercise	62.44	145,413	9,079,689	245,012	Nov 29 08:10 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Sale	91.92	164,211	15,094,013	80,801	Nov 29 08:10 PM
ANDREW DICKINSON	Officer	Nov 29 '24	Proposed Sale	92.76	248,645	23,065,258		Nov 29 02:35 PM
Bluestone Jeffrey	Director	Nov 26 '24	Option Exercise	61.24	10,000	612,442	15,708	Nov 27 06:14 PM
Bluestone Jeffrey	Director	Nov 26 '24	Sale	91.39	6,788	620,356	8,920	Nov 27 06:14 PM
MERDAD V PARSEY	Officer	Nov 27 '24	Proposed Sale	91.92	164,211	15,094,008		Nov 27 04:15 PM
Bluestone Jeffrey	Director	Nov 26 '24	Proposed Sale	91.39	6,788	620,356		Nov 26 07:31 PM
Mercier Johanna	Chief Commercial Officer	Nov 06 '24	Sale	91.28	5,000	456,400	73,127	Nov 07 04:38 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Option Exercise	57.92	25,000	1,448,000	125,189	Nov 07 04:32 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Sale	91.50	25,590	2,341,485	99,599	Nov 07 04:32 PM
MERDAD V PARSEY	Officer	Nov 06 '24	Proposed Sale	91.50	25,590	2,341,485		Nov 06 04:19 PM
JOHANNA MERCIER	Officer	Nov 06 '24	Proposed Sale	91.28	5,000	456,400		Nov 06 04:07 PM
Parsey Merdad	Chief Medical Officer	Oct 01 '24	Sale	83.83	2,000	167,660	100,189	Oct 02 04:58 PM
MERDAD V PARSEY	Officer	Oct 01 '24	Proposed Sale	83.83	2,000	167,660		Oct 01 04:27 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Option Exercise	57.92	25,000	1,448,000	123,435	Sep 13 07:07 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Sale	84.50	21,246	1,795,287	102,189	Sep 13 07:07 PM
Mercier Johanna	Chief Commercial Officer	Sep 12 '24	Sale	83.78	29,357	2,459,577	78,127	Sep 13 05:08 PM
MERDAD V PARSEY	Officer	Sep 12 '24	Proposed Sale	84.50	21,246	1,795,287		Sep 12 04:45 PM
JOHANNA MERCIER	Officer	Sep 12 '24	Proposed Sale	83.78	29,357	2,459,577		Sep 12 04:43 PM
Mercier Johanna	Chief Commercial Officer	Aug 28 '24	Sale	78.03	9,513	742,299	105,466	Aug 29 03:23 PM
JOHANNA MERCIER	Officer	Aug 28 '24	Proposed Sale	78.03	9,513	742,299		Aug 28 04:18 PM
Mercier Johanna	Chief Commercial Officer	Aug 13 '24	Sale	73.98	5,490	406,150	114,979	Aug 14 02:23 PM
JOHANNA MERCIER	Officer	Aug 13 '24	Proposed Sale	73.98	5,490	406,150		Aug 13 04:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc

Upgrade your FINVIZ experience